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Abstract: Chronic lymphocytic leukemia (CLL) is a biologically heterogeneous illness that 
primarily afflicts the elderly. For many decades, the initial therapy for most patients requiring 
treatment was limited to single-agent alkylator therapy. Within the last two decades, we have 
seen remarkable progress in understanding the biology of CLL and the development of more 
effective treatment strategies that have employed monoclonal antibodies, such as rituximab 
  (anti-CD20). Furthermore, recognition of the synergy between fludarabine, cyclophosphamide, 
and rituximab (FCR) prompted investigators to explore the clinical activity of FCR in Phase II 
and III trials in patients with relapsed/refractory or previously untreated CLL. On the basis of 
these findings, the US Food and Drug Administration (FDA) recently approved rituximab in 
  combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed/
refractory or previously untreated CD20-postive CLL. Recent data from a randomized Phase III 
trial has confirmed improved overall survival with FCR in patients with previously untreated CLL. 
  However, FCR is not for everyone. More tolerable regimens using rituximab for the elderly and 
less fit patients are being pursued in clinical trials. Recent Phase II trials have explored potentially 
less myelosuppressive approaches by using lower doses of fludarabine and cyclophosphamide, 
replacing fludarabine with pentostatin, and combining rituximab with chlorambucil. Furthermore 
new biomarkers predictive of early disease progression have prompted investigators to explore 
the benefits of early treatment with rituximab combined with other agents. In addition to the 
proven utility of rituximab as a frontline agent for CLL, rituximab has a favorable toxicity 
profile both as a single agent and in combination with chemotherapy. The majority of adverse 
events are Grade 1 and 2 infusion-related reactions (fevers, chills, and rigors) and occur with 
the first dose of rituximab. The improved tolerability observed with second and subsequent 
infusions allows for shorter infusion times. Rituximab’s proven activity and favorable toxicity 
profile has made it an ideal agent for expanding treatment options for patients with CLL, the 
majority of whom are elderly.
Keywords: rituximab, tolerability, chronic lymphocytic leukemia, fludarabine, pentostatin, 
chlorambucil, elderly
Introduction
Chronic lymphocytic leukemia (CLL), a monoclonal B cell malignancy, is the most 
common adult leukemia in the Western hemisphere and primarily affects the elderly. 
The median age at diagnosis is 72 years, and more than two-thirds of the patients 
are older than 65 years.1 The clinical course of CLL is highly variable. Many cases 
behave indolently for decades and never require treatment, while others die from a 
rapid progression of the disease within a few years of diagnosis. Because the majority 
of CLL patients are asymptomatic at presentation and there exists a lack of evidence Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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demonstrating a survival advantage with early treatment,2 
most patients do not require treatment until evidence of 
disease progression.
For many years, the initial therapy for CLL consisted of 
single-agent alkylators, such as chlorambucil, capable of 
achieving objective response rates in 60%–70% of patients 
but low complete remission rates.2–4 However, advances in 
understanding the biology of the disease, identification of 
high-risk biologic features, and the introduction of rituximab 
(Rituxan®; Genentech, Inc., South San Francisco, CA and 
Biogen Idec, Inc, Cambridge, MA) have markedly changed 
the treatment landscape for CLL.
Rituximab is a chimeric human-mouse monoclonal anti-
body with a high affinity for the CD20 surface antigen, a trans-
membrane protein that is expressed on pre-B cells and normal 
differentiated B lymphocytes. Rituximab binds a discontinu-
ous epitope in CD20, comprised of amino acids 170–173 and 
182–185, with both strings brought in steric proximity by a 
disulfide bridge between C(167) and C(183).5 Binding of 
rituximab to the CD20 antigen elicits a response that results 
in rapid and durable depletion of normal and malignant B cells 
via multiple mechanisms that include antibody-dependent 
cellular cytotoxicity, complement-dependent cytotoxicity, 
and direct induction of apoptosis.6–8 Stem cells and plasma 
cells are spared because they lack CD20 antigens.9
Single-agent rituximab has clinical activity in previously 
treated and untreated CLL. Discovery of synergistic activity 
between conventional chemotherapy and rituximab prompted 
investigators to explore an array of novel combination 
regimens in previously untreated CLL. The most effective 
regimen combines rituximab with fludarabine and cyclo-
phosphamide (FCR). The FCR regimen yields high complete 
remission rates and was the first regimen to improve overall 
survival significantly in CLL. On the basis of these findings, 
rituximab received approval by the US FDA for the indication 
of relapsed/refractory or previously untreated CD20-positive 
CLL in combination with fludarabine and cyclophosphamide. 
Treatment with single-agent alkylators is now reserved for 
elderly patients and biologically unfit patients with comor-
bidities that prevent them from receiving more myelosuppres-
sive therapy. For this subgroup, investigators are exploring 
less myelosuppressive regimens involving rituximab.
Therapeutic potential of single-
agent rituximab in CLL
Previously treated patients
The therapeutic potential of rituximab for CLL was real-
ized from its reported activity (overall response 50%) 
in previously treated low-grade and follicular B cell 
lymphomas.10–12 In a pivotal study, rituximab 375 mg/m2 
given intravenously (IV) as monotherapy to previously 
treated CLL and small lymphocytic leukemia patients 
demonstrated limited activity (overall response 13%) 
and durability.12,13 The poor performance of rituximab in 
these studies may have been due to the low expression of 
CD20 antigens on CLL cells, whereas malignant B cells 
from patients with follicular lymphoma are more densely 
populated with CD20 antigens.14 Secondly, rituximab may 
bind to circulating CD20-positive cellular debris gener-
ated from prior cytotoxic therapies, thus rendering CLL 
cells less vulnerable to rituximab.   However, subsequent 
studies investigating dose-dense (thrice weekly) rituximab 
and higher weekly doses of rituximab 500–2250 mg/m2 in 
previously treated patients reported modest overall response 
rates of 43% and 40%, respectively,15–17 and the latter study 
revealed a correlation between the dose of rituximab and 
the clinical response.16 Additionally, the thrice weekly 
regimen produced a modest complete remission rate of 3%, 
but patients   harboring a 17p13.1 deletion did not achieve 
a meaningful response with this regimen. Nonetheless, the 
activity demonstrated by rituximab in these studies sup-
ported the rationale for investigating single-agent rituximab 
in treatment-naïve CLL, as summarized in Table 1.
Treatment-naïve patients
In a study conducted by Thomas et al,18 eight weekly doses of 
rituximab 375 mg/m2 were given to 21 previously untreated, 
early-stage (Rai 0–II), asymptomatic CLL patients with 
beta2-microglobulin (B2M) $ 2 mg/dL. The overall response 
rate reported was 90%, and 19% of these patients experienced 
a complete response. In a different single-agent rituximab 
study by Hainsworth et al,19 44 previously untreated, symp-
tomatic patients with CLL or small lymphocytic leukemia 
who received four weekly doses of rituximab 375 mg/m2 
achieved overall response and complete response rates of 
51% and 4%, respectively. An additional four-week course 
Table 1 Single agent rituximab studies in treatment-naïve chronic 
lymphocytic leukemia
Reference Doses N OR (%) CR (%) Median PFS   
(months)
Thomas et al18  4 21 90 19 43
Hainsworth et al19 4 
8
44 
28a
51 
58
4 
9
19
Note: aPatients who received additional maintenance therapy with rituximab.
Abbreviations: N, evaluable patients; OR, overall response; CR, complete remission; 
PFS, progression-free survival.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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of rituximab given every six months for up to four cycles 
to 28 patients with stable or responsive disease slightly 
increased the overall response rate to 58% and the complete 
response rate to 9%. Median progression-free survival was 
19 months, similar to that achieved by single-agent fludara-
bine in the frontline setting. The promising activity demon-
strated by single-agent rituximab in these studies provided the 
rationale for expanding its role by coadministering rituximab 
with chemotherapy.
Chemoimmunotherapy  
with rituximab
Fludarabine–rituximab regimen
Chemoimmunotherapy regimens with rituximab have   markedly 
changed the treatment landscape for previously untreated 
patients with CLL. This transformation began with the intro-
duction of purine nucleoside analogs, such as   fludarabine, 
demonstrating superior response rates to   single-agent alky-
lator-based therapy in CLL.20 As   monotherapy,   fludarabine 
was associated with high overall response rates and modest 
complete response rates of 20% to 30%,20–23 but relapse was 
inevitable. Being the most active agent for CLL at the time, 
further exploration of fludarabine-based combinations such 
as fludarabine and rituximab (FR) was conceived. The proven 
antileukemic activity of both agents, in vitro synergistic 
  antitumor activity,24,25 and lack of overlapping toxicity inspired 
Schultz et al26 to conduct a Phase II trial to investigate the 
safety and efficacy of FR in 31 CLL patients, 20 of whom 
were previously untreated. Fludarabine 25 mg/m2/day was 
given IV on days 1–5 every 28 days for four cycles. Beginning 
with the third cycle,   rituximab 375 mg/m2 was given monthly 
on day 1 for four doses. The FR regimen yielded an overall 
response rate of 87% and a complete response rate of 33%, 
while 85% and 25% of the treatment-naïve patients achieved 
an overall response and complete response, respectively. The 
median duration of response was 18.8 months.
Summarized in Table 2, the Cancer and Leukemia Group B 
(CALGB) also conducted a Phase II study (CALGB 9712) to 
determine the optimal positioning of rituximab when com-
bined with fludarabine.27 This Phase II study randomized 104 
previously untreated patients with CLL to receive six monthly 
cycles of IV fludarabine 25 mg/m2/day for five   consecutive 
days in combination with rituximab,   concurrently or sequen-
tially. Patients randomized to the concurrent rituximab arm 
received rituximab 375 mg/m2 on days 1 and 4 in cycle 1 and 
on day 1 in cycles 2–6, followed two months later with four 
weekly doses of   rituximab in patients who demonstrated a 
response or had stable disease. Similarly, the sequential arm 
consisted of four weekly doses of rituximab two months after 
completion of fludarabine for responders or those with stable 
disease. The concurrent group experienced higher overall 
response and complete response rates than the sequential 
group (90% and 47% versus 77% and 28%, respectively) at 
the expense of higher grade 3 or 4 neutropenia. Despite the 
higher response rates observed in the concurrent group, a 
long-term follow-up revealed similar estimated overall survival 
and progression-free survival between the two groups.28 In a 
subsequent analysis, patients treated with FR in the CALGB 
9712 trial were retrospectively compared with a similar 
control group treated with fludarabine alone in the CALGB 
9011 trial. The retrospective analysis revealed a significantly 
higher progression-free survival and overall survival in the FR 
group (CALGB study 9712) than for single-agent fludarabine. 
Although this promising evidence was not generated from a 
randomized study, the suggestion of a survival advantage was 
enough to change the approach to treating CLL.29
Fludarabine–cyclophosphamide– 
rituximab regimen
Combining fludarabine and cyclophosphamide (FC) provided 
an additive advantage that translated into improved remission 
rates, progression-free survival, and treatment-free survival.30–32 
Striving for a complete response rate higher than 50%, inves-
tigators at MD Anderson   Cancer Center (MDACC) added 
rituximab to FC and treated 300 previously untreated patients 
with advanced CLL in a single-center Phase II study.33 The first 
cycle of FCR consisted of rituximab 375 mg/m2 on day 1 and 
IV fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/
m2/day on days 2, 3, and 4. In cycles 2–6, the rituximab dose 
was increased to 500 mg/m2 on day 1 and fludarabine and 
cyclophosphamide were administered on days 1, 2, and 3 as 
well. Courses were repeated every four weeks for a total of 
six courses, and growth factor support was used at the discre-
tion of the treating physician. The median age of the patients 
was 57 years and 14% of the patients were over 70 years. The 
majority of patients had Rai stage I or II disease. After a median 
follow-up of six years, the overall response rate was 95% and 
the complete response rate was 72%, the highest response 
rates reported with any frontline regimen for CLL. The overall 
survival and failure-free survival rates at six years were 77% 
and 51%, respectively.34 Compared with a historic group of 
patients who received frontline fludarabine-based regimens 
at MDACC, the   complete response rate and overall survival 
appeared significantly better with FCR. Moreover, 78% of 
the patients achieving a complete response were also negative 
for minimal residual disease as assessed by flow cytometry, Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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defined as CD5- and CD19-coexpressing cells less than 1%, 
with normalization of the kappa:lambda ratio (,3:1 in patients 
with monotypic kappa and .1:3 in patients with monotypic 
lambda). Minimal residual disease negativity was associated 
with superior survival (84% at six years versus 65% by flow 
cytometry positivity; P = 0.001). In addition, patients with 
some high-risk features and age 70 years or older were associ-
ated with inferior response rates. From the long-term follow-up, 
the rate of serious infections was highest in the first year of 
remission (10%) and declined rapidly to less than 1.5% per year 
by the third year. The occurrence of opportunistic infections 
was limited to the first year.33 However, the incidence of dose 
reductions was significantly higher in patients older than 60 
years and in patients with Rai stage IV disease.
These favorable results from MDACC prompted 
the   German CLL Study Group (GCLLSG) to conduct a 
  multicenter, international Phase III randomized trial (CLL8) 
comparing FCR with FC as frontline therapy for CLL.35 
The GCLLSG randomized 817 physically fit CLL patients 
to receive six monthly cycles of FC or FCR, using the same 
dosing regimen as the MDACC trial. The median patient 
age was 61 years and the majority of patients were Binet stage 
B or C. The interim report included 761 patients evaluable for 
response, 790 patients evaluable for progression-free survival, 
and all patients were evaluable for overall survival. After 
a median follow-up of 37.7 months, FCR yielded a higher 
overall response rate (95.1% versus 88.4%), higher complete 
response rate (44.1% versus 21.8%; P , 0.001) and longer 
progression-free survival (51.8 months versus 32.8 months; P 
, 0.001) compared with FC. Likewise, superior overall sur-
vival was observed with the FCR arm compared with the FC 
arm (84.1% and 79.0%; P = 0.01). The largest survival benefit 
after FCR treatment was seen in patients with Binet stages A 
and B. The FCR regimen was associated with more hemato-
Table 2 Studies exploring chemoimmunotherapy with rituximab in treatment-naïve chronic lymphocytic leukemia
Reference Phase N Regimen(s) OR (%) CR (%) Median survival 
(months)
Single-arm studies
Keating et al33 and  
Tam et al34
ii 300 Fludarabine +  
Cyclophosphamide +  
Rituximab (FCR)
95 72 NR
O’Brien et al36 ii 65 Fludarabine +  
Cyclophosphamide +  
Rituximab × 3 days (FCR3)
94 65 NR
Foon et al37 ii 50 Fludarabine (↓20%) +  
Cyclophosphamide (↓40%) +  
Rituximab × 2 days (FCR-Lite)
100 77 NR
Kay et al38 ii 64 Pentostatin +  
Cyclophosphamide +  
Rituximab (PCR)
91 41 PFS:33
Kay et al39 ii 33 Pentostatin + Rituximab (PR) 76 27 TFS:16
Bosch et al40 ii 67 Fludarabine +  
Cyclophosphamide +  
Mitoxantrone +  
Rituximab (FCMR)
93 82 NR
Faderl et al47 ii 30 Fludarabine +  
Cyclophosphamide +  
Mitoxantrone +  
Rituximab (FCMR)
96 83 NR
Fischer et al52 ii 117 Bendamustine + Rituximab (BR) 91 33 NR
Randomized Studies
Byrd et al27 and  
woyach et al28
ii 104 Fludarabine + Rituximab (FR)  
(Concurrent)  
Fludarabine + Rituximab (FR)  
(Sequential)
90  
 
77
47  
 
28
OS:84; PFS:32  
 
OS:91; PFS:40
Hallek et al35 iii 817 Fludarabine + Cyclophosphamide +  
Rituximab (FCR)  
Fludarabine + Cyclophosphamide (FC)
95 
 
88
44  
 
22
PFS:52; OS:NR  
 
PFS:33; OS:NR
Abbreviations:  N,  evaluable  patients;  OR,  overall  response; CR,  complete  remission;  OS,  overall  survival;  PFS,  progression-free survival;  FFS,  failure-free  survival;   
TFS, treatment-free survival; NR, not reported or reached.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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logic adverse events, particularly neutropenia. However, this 
did not result in an increased infection rate. This was the first 
randomized trial demonstrating an overall survival advantage 
with chemoimmunotherapy. Although the MDACC and 
GCLLSG studies produced similar overall response rates, the 
complete response rate was lower in the GCLLSG study. The 
lower complete response rate in CLL8 than in the MDACC 
trial may be attributed to a difference in patient demographics. 
The patients in CLL8 were older and a smaller proportion of 
the patients in CLL8 were Binet stage A.
Improving on the fludarabine–
cyclophosphamide–rituximab 
regimen
FCR-3 regimen
Despite the recent advances in the development of new 
  treatment strategies, there is no evidence yet that these 
new and effective treatments are curative. Therefore, in 
an attempt to increase the activity of FCR and based on 
the dose-response data with rituximab in relapsed CLL 
patients,16 investigators at MDACC increased the rituximab 
dose to three infusions per cycle (FCR-3, Table 2). O’Brien 
et al36 treated 65 CLL patients with the FCR-3 regimen, 
which consisted of three consecutive days of IV   fludarabine 
25 mg/m2/day, cyclophosphamide 250 mg/m2/day, and 
  rituximab 375 mg/m2 as the first dose and rituximab 
500 mg/m2/day for all subsequent doses every 28 days for six 
cycles. In short, the trial failed to reveal any additional benefit 
by adding two additional daily doses of rituximab to FCR.
FCR-Lite regimen
Additionally, there still exists an elderly population (70 years 
and older) that may not be able to tolerate FCR. As summa-
rized in Table 2, several investigators have explored modifi-
cations to the FCR regimen in an attempt to reduce toxicity, 
while maintaining or improving upon the excellent response 
rates reported by the MDACC experience. Another approach 
was to decrease the daily doses of fludarabine and cyclo-
phosphamide by 20% and 40%, respectively, and increase 
the monthly exposure to rituximab. In a recent Phase II study 
by Foon et al37 50 treatment-naïve patients were treated with 
six cycles of FCR-Lite every four weeks. FCR-Lite consisted 
of IV fludarabine 20 mg/m2/day and IV cyclophosphamide 
150 mg/m2/day for three consecutive days, days 2–4 dur-
ing cycle 1, and days 1–3 during cycles 2–6. Rituximab 
375 mg/m2 was administered on day 1 of cycle 1 and 500 mg/m2 
was administered on day 14 of cycle 1 and days 1 and 14 in 
subsequent cycles. Following completion of six cycles, 
rituximab 500 mg/m2 was given as maintenance therapy once 
every three months until relapse. Similar to the MDACC 
experience, high overall response (100%), complete response 
(77%), and minimal residual disease negative rates were 
observed with this regimen. The designed reduction in FC 
doses and use of granulocyte colony-stimulating factor most 
likely contributed to the reduction in Grade 3 or 4 neutropenia 
(13%). However, the impact of this regimen on survival has 
not been determined.
Pentostatin–cyclophosphamide– 
rituximab regimen
Also in pursuit of a less myelosuppressive regimen without 
sacrificing antileukemic activity, investigators at the Mayo 
Clinic and The Ohio State University replaced fludarabine 
in the FCR regimen with pentostatin (PCR). In a   single-arm 
Phase II study,38 65 symptomatic and previously untreated 
CLL patients were treated with pentostatin 2 mg/m2, cyclo-
phosphamide 600 mg/m2, and rituximab 375 mg/m2 for one 
day every 21 days for six cycles. Of note, rituximab 100 mg/m2 
was given on day 1 and 375 mg/m2 on days 3 and 5 during 
the initial cycle. Support from granulocyte colony-stimulating 
growth factor was provided. Sixty-four patients were evaluable 
in this study and 34 (53%) were Rai stages 3 or 4. The median 
age of the patients was 63 years, and 18% of the patients were 
70 years or older. The overall response rate reported with PCR 
was 91%, the   complete response rate was 41%, and median 
progression-free survival was 32.6 months. Similar to the FCR 
experience, patients who achieved minimal residual disease 
negativity by two-color flow cytometry had significantly 
longer survival, demonstrating the clinical benefit of acheiving 
MRD negative status. Grade 3 or 4 neutropenia and infections 
occurred in 16% and 2% of the cycles, respectively. The initial 
expectation with the PCR regimen was that the infectious 
complications would be less than with the FCR regimen. 
However, a randomized community-based trial in previously 
untreated or minimally pretreated patients reported a better 
complete response rate with FCR with a comparable overall 
response rate, cytopenias, and infectious complications.
Pentostatin–rituximab regimen
In an effort to maintain the response observed using PCR, and 
improve upon the tolerability of the pentostatin-based   regimen, 
Kay et al39 removed the cyclophosphamide and treated a small 
cohort of treatment-naïve patients (n = 33) with a higher dose 
of pentostatin 4 mg/m2 and the same dose and schedule of 
rituximab as used in the PCR regimen. This regimen was well 
tolerated, with only 12% experiencing grade 3   hematologic Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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events and 15% with grade 3 or higher nonhematologic toxicity. 
The overall response rate was 76% with 9 patients achieving a 
complete response. Compared to the previously reported PCR, 
the PR regimen yielded inferior overall response and complete 
response rates and shorter treatment-free survival.
Fludarabine–cyclophosphamide–
mitoxantrone–rituximab regimen
The addition of rituximab to combination chemotherapy 
  consisting of fludarabine, cyclophosphamide, and mitox-
antrone (FCM) was explored in a recent Phase II study.40 
Justification for this approach evolved from preclinical 
evidence demonstrating synergism between these agents,42,43 
efficacy of FCM in previously treated and untreated CLL 
patients,41,44,45 and efficacy associated with rituximab-based 
chemoimmunotherapy in previous studies. In a multicenter 
Phase II trial, 77 previously untreated CLL patients (median 
age, 60 years) with active disease defined by National 
Cancer Institute-Working Group46 received combination 
therapy   consisting of rituximab 375 mg/m2 in cycle 1, and 
500 mg/m2 in subsequent cycles, IV fludarabine 25 mg/m2 
for three days, IV cyclophosphamide 200 mg/m2 for three 
days, and IV mitoxantrone 6 mg/m2 on day 1 for a total of six 
cycles, followed by maintenance therapy with rituximab every 
three months in responders. With assistance from granulo-
cyte colony-stimulating growth factors, 88% of the patients 
  completed the full course of therapy. A high overall response 
of 93% and complete response of 82% were achieved, and 
46% of the patients achieving a   complete response were 
negative for minimal residual disease.   Subgroup analysis 
of toxicity showed more severe neutropenic episodes and 
infectious episodes in patients aged 60–70 years.
In a second Phase II study, mitoxantrone was added 
to FCR and used as frontline therapy in a small cohort of 
30 patients, aged less than 70 years and with a B2M # 
twice the upper limit of normal.47 Compared with a historic 
group of patients treated with FCR, similar overall response, 
complete response, and minimal residual disease-negative 
rates were achieved (96%, 83%, and 67% by flow cytometry, 
  respectively). Thus, the benefit for adding mitoxantrone to the 
FCR regimen is not so evident from these studies.
Bendamustine–rituximab regimen
With the availability of new cytotoxic agents having activity 
in CLL, more opportunities to explore the benefit of adding 
rituximab are possible. Bendamustine (Treanda®; Cephalon, 
Inc, West Chester, PA) is an alkylating agent with cytotoxic 
properties similar to those of the purine nucleoside analogs. 
Single-agent bendamustine was approved in 2008 by the 
FDA for the treatment of CLL and rituximab-refractory 
non-Hodgkin’s lymphoma. The efficacy of bendamustine as 
monotherapy for CLL has been demonstrated in several Phase 
I and II trials.48,49 Based on in vitro evidence demonstrating 
synergy between bendamustine and rituximab in CLL cell 
lines,50 and encouraging evidence of this combination in 
the relapsed and/or refractory CLL setting,51 the GCLLSG 
investigated the bendamustine–rituximab (BR) regimen in 
treatment-naïve CLL patients. In a Phase II study,52 BR was 
administered to 117 previously untreated CLL patients. The 
median age was 64 years, and nearly half the patients were 
Binet stage C. The BR regimen consisted of bendamustine 
90 mg/m2/day IV for two consecutive days every 28 days for 
six cycles and rituximab 375 mg/m2 for the first cycle and 
500 mg/m2 for cycles 2–6. The overall response rate was 91%, 
with 33% (36 of 110 patients) of the patients experiencing a 
complete response. Although the response rate was lower than 
for FCR, fewer neutropenic events and infectious complica-
tions were observed. These promising findings prompted the 
GCLLSG to conduct an ongoing Phase III trial comparing 
BR with FCR in previously untreated CLL patients.53
Novel rituximab combinations  
for high-risk and elderly patients
Fludarabine–cyclophosphamide 
alemtuzumab–rituximab regimen
A subgroup analysis of patients with high-risk features in 
the FCR trial by MDACC revealed lower complete response 
rates, and shorter time to progression and overall survival.34 
With this in mind and the positive data from a previous 
study using cyclophosphamide, fludarabine, alemtuzumab, 
and rituximab (CFAR) in relapsed/refractory patients, 
  investigators at MDACC explored the CFAR regimen in 60 
previously untreated high-risk patients who had a 17p   deletion 
or B2M level higher than twice the upper limit of normal 
(Table 3).54,55 Frontline CFAR consisted of 200 mg/m2 of IV 
cyclophosphamide and 20 mg/m2 of IV fludarabine on days 
3, 4 and 5, 30 mg of alemtuzumab IV on days 1, 3, and 5, and 
375–500 mg/m2 rituximab on day 2. Courses were repeated 
every 28 days for a total of six courses. CFAR achieved a 
92% overall response and 70% complete response rate in this 
high-risk group. Notably, 52% (8/14) of the patients with a 
17p deletion attained a complete response, but experienced 
a shorter time to progression compared with all evaluable 
patients (18 months versus 38 months,   respectively). Similar 
rates of Grade 3/4 cytopenias and infections were seen with 
these patients when compared with a historic high-risk group Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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of patients who received FCR. The data suggest that CFAR is 
a highly active regimen as frontline therapy for high-risk CLL 
and deserves further exploration in the setting of a clinical 
trial to determine the long-term effects of this combination.
Alemtuzumab–rituximab monoclonal 
antibody regimen
Alemtuzumab (CAMPATH 1H; Genzyme, Cambridge, 
MA) is a humanized monoclonal antibody directed at the 
CD52 antigen that is expressed on both B lymphocytes 
and T lymphocytes. Several studies have demonstrated the 
effectiveness of single-agent alemtuzumab in the salvage 
setting56,57 and as initial58,59 therapy for CLL. Alemtuzumab 
has remarkable activity in CLL patients resistant to purine 
nucleoside analogs and harboring the p53 mutation which 
confers a poor prognosis.60,61 Alemtuzumab is effective at 
clearing the bone marrow of disease, but has limited activity in 
clearing the bulky lymphadenopathy that can be accomplished 
with rituximab. By virtue of these complementary actions, 
a novel early treatment approach using these monoclonal 
antibodies in combination for CLL patients with high-risk 
features was explored in a single-center Phase II study. 
Investigators at the Mayo Clinic, Rochester, set out to deter-
mine if chemo-naive CLL patients harboring at least one 
of the high-risk biologic abnormalities, deletions 17p13, 
11q22, or a combination of unmutated IgVH and CD38 or 
ZAP70 positivity, would benefit from early intervention 
with alemtuzumab and rituximab rather than delaying 
therapy until disease progression.62 Shown in Table 3, this 
Phase II single-center study treated 30 early-stage (Rai 0–II) 
high-risk patients who lacked an indication for treatment by 
National Cancer Institute-Working Group 1996 criteria,46 
with   rituximab and alemtuzumab (RA) in combination. This 
monoclonal antibody combination consisted of a gradual dose 
escalation of alemtuzumab from 3 mg to 10 mg then 30 mg 
by subcutaneous injection daily over three days during the 
first week, followed by alemtuzumab 30 mg thrice weekly for 
four weeks. Beginning the second week of therapy, rituximab 
375 mg/m2 was administered weekly for a total of four 
weeks. All patients received prophylaxis for Pneumocystis 
jirovecii pneumonia, herpes simplex, and varicella zoster 
virus, and were monitored for cytomegalovirus reactivation. 
Twenty-seven patients (90%) responded to therapy and 
11 patients (37%) experienced a complete response. Five 
patients with a complete response achieved minimal residual 
disease negativity by immunohistochemical analysis and 
flow cytometry. The median duration of response in the 27 
responders was 14.4 months and the patients who achieved 
remissions with minimal residual disease negativity 
experienced the best response durations. Compared with 
a historic cohort of untreated patients who were similar in 
age, clinical Rai stage, and risk features, the median time 
from diagnosis to treatment was longer for patients who 
received RA than for the untreated control group (4.4 years 
and 1.9 years, respectively; P = 0.001). Interestingly, the 
patients who progressed were tested for clonal selection or 
Table 3 Studies exploring novel combinations with rituximab in treatment-naïve high-risk or elderly chronic lymphocytic leukemia
Reference Patient  
characteristics
N Regimen(s) OR (%) CR (%) Median survival   
(months)
wierda et al54 and 
Parikh et al55
Median age: 59 yrs 
Median B2M: 5.1 mg/L 
Rai stage iii–iv: 51%
59 Cyclophosphamide +  
Fludarabine + 
Alemtuzumab + 
Rituximab (CFAR)
72 92 NR
Zent et al62 Median age: 61 yrs 
Rai stage 0–ii: 100% 
11q- or 17p-: 57% 
UM igvH + ZAP-70+  
± CD38+: 43%
30 Rituximab + 
Alemtuzumab (RA)
90 37 NR
Hillmen et al63 Median age: 70.5 yrs 
Binet C: 52%
47 Chlorambucil + 
Rituximab (CHl-R)
84 NR NR
Castro et al64 Median age: 65 yrs 
Age . 70: 29%  
11q- or 17p-: 14%
UM igvH: 53%
ZAP-70+: 
CD38+: 32%
28 HDMP + 
Rituximab (HDMP-R)
96 32 PFS:30
Abbreviations: N, evaluable patients; B2M, beta2-microglobulin; UM, unmutated; IgVH, immunoglobulin heavy chain genes; ZAP-70, zeta chain-associated protein kinase 
70 kDa; ZAP-70+, $ 20% expression; CD38+, $ 30% expression; -, indicates deletion; HDMP, high-dose methylprednisolone; OR, overall response; CR, complete 
remission; PFS, progression-free survival; NR, not reported or reached; yrs, years.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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evolution and found to have no evidence of new aggressive 
clones, which suggests that early treatment with monoclonal 
antibodies may not contribute to disease resistance or limit 
future treatment options.
Chlorambucil–rituximab regimen
Despite the advancements in the treatment of CLL, an elderly 
population unable to tolerate intensive cytotoxic therapy 
still exists and chlorambucil remains a viable treatment 
option. To improve upon the response rates demonstrated 
by chlorambucil alone in previous trials,2–4 Hillman et al63 
recently treated 100 elderly patients (median age 70.5 years) 
with a combination regimen consisting of chlorambucil and 
rituximab. Chlorambucil 10 mg/m2/day was administered 
orally for the first seven days of each month with rituximab 
375 mg/m2 on the first day of course 1 followed by rituximab 
500 mg/m2 on the first day of each subsequent course. Each 
course was repeated every 28 days for six total courses and 
responding patients were permitted to continue six additional 
cycles of chlorambucil monotherapy. Summarized in Table 3, 
the interim intent-to-treat analysis on 50 patients, 47 of whom 
were evaluable for response, revealed an overall response 
rate of 84%. Compared with a similar group who received 
chlorambucil alone in the LRF CLL4 trial, the patients treated 
with chlorambucil and rituximab demonstrated a 17.3% 
higher overall response rate. Grade 3 or 4 neutropenia was 
still observed in 40% of the patients.
High-dose methylprednisolone– 
rituximab regimen
Frontline use of rituximab in combination with high-dose 
methylprednisolone 1 gm/m2 has also been studied in an elderly 
population with a median age of 65 years. The administration 
of both agents for three consecutive days for three cycles every 
four weeks has been reported to have an overall response and 
complete response rate of 96% and 32%, respectively, in a trial 
involving 28 patients.64 Two patients achieved MRD-negative 
bone marrows by four-color flow cytometry. Regardless of 
MRD status, patients who achieved a CR experienced a lon-
ger median PFS than those who did not acheive a CR (40.3 
months and 23.9 months, respectively). Interestingly, patients 
with high-risk features such as elevated ZAP-70 expression 
and CD38, unmutated IGVH, unfavorable cytogenetics, and 
bulky lymphadenopathy achieved similar response rates as 
those who did not have these disease features. All patients older 
than 70 years responded and three patients achieved a complete 
response. Hyperglycemia, fatigue, sinusitis, and dyspepsia were 
the most common adverse events. Of particular interest is the 
encouraging clinical activity of this regimen and its favorable 
toxicity profile that makes it a potential treatment option for 
older patients not eligible for more aggressive approaches.
Tolerability of rituximab
Early Phase I and II studies using rituximab in CD20-positive 
B cell lymphomas established the activity and toxicity potential 
of rituximab.12,65 In a pivotal trial consisting of single-agent 
rituximab in indolent lymphomas, rituximab was shown to be 
generally well tolerated.11 The majority (96%) of adverse events 
were Grade 1 or 2 infusion-related   reactions and occurred 
during the first infusion. However, over half of the patients 
remained free of adverse events with the second and subsequent 
  infusions11 The majority of infusion-related reactions consisted 
of fever, chills, and rigors, and less commonly, hypotension 
and bronchospasm. Some studies suggest that cytokine release 
may be partially responsible for infusion-related reactions and 
a high number of circulating lymphocytes is predictive of an 
infusion-related reaction.66–68 However, subsequent studies have 
shown no correlation between high circulating lymphocytes 
and infusion-  related reactions.14,19 Regardless, management of 
  infusion-related reactions begins with prevention.   Premedicating 
rituximab with acetaminophen and an antihistamine will reduce 
the incidence and severity of infusion-related reactions. For 
patients who appear to be at high risk for infusion-related 
reactions, a steroid such as hydrocortisone can be administered 
in addition to the other premedications.
Combining rituximab with chemotherapy has been 
extensively studied in CLL. Several randomized studies 
have shown that the pattern of adverse events of rituximab-
based chemoimmunotherapy is broadly similar to the 
  comparator   regimen with the exception of higher Grade 3 
or 4   neutropenia that was not associated with an increased 
risk of infection.27,35
Tumor lysis syndrome is also a well documented   toxicity 
which generally affects patients with high tumor burden and/or 
high circulating tumor cells and occurs within the first 24 hours 
of the first treatment with rituximab.68,69 This syndrome can 
manifest as renal failure, hyperuricemia, hyperkalemia, and/
or hyperphosphatemia, and patients require close monitoring, 
adequate hydration, correction of electrolyte abnormalities, 
and dialysis as needed. Prior to starting treatment, patients 
should be well hydrated, receive prophylaxis with allopurinol 
or rasburicase, and be observed closely.
Other rare but serious toxicities include hypersensitivity 
pneumonia, mucocutaneous reactions, and hepatitis B virus 
reactivation. Case reports of fatal reactivation of hepatitis B 
virus in patients with B cell malignancies following rituximab Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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therapy have been described.70–72 Therefore, patients should 
be screened for hepatitis B virus prior to starting rituximab, 
and rituximab should be discontinued in patients who develop 
viral hepatitis. Prophylaxis against hepatitis B virus reacti-
vation should be considered for those with evidence of past 
exposure. Although rare, a recent report describes 57 cases 
of progressive multifocal leukoencephalopathy following 
therapy with rituximab.73 Multifocal leukoencephalopathy is 
a demyelinating disease of the central nervous system caused 
by the reactivation of JC polyoma virus. The mechanism 
behind the reactivation of virus following rituximab therapy 
is not known. Currently, there is no satisfactory treatment for 
the disease and most cases are fatal.
Tolerability of rapid  
infusion rituximab
Due to the potential for infusion-related reactions as described 
earlier, rituximab was approved to be administered via slow 
IV infusion (rate escalation schedule) over 5–6 hours for the 
initial infusion and over 3–4 hours for subsequent infusions 
as tolerated. The approved administration time is inconvenient 
for patients and incurs high resource demands for infusion 
centers. Therefore, over the past five years, many institutions 
have evaluated the safety and tolerability of a shorter infusion 
time, ie, 60- or 90-minute infusions, for second and subsequent 
rituximab cycles. Studies administering rituximab over a total 
of 90 minutes (20% of the dose given over 30 minutes and the 
remaining 80% over 60 minutes, with standard premedications 
with or without corticosteroids) elicited only Grade 1 infusion-
related toxicities and no Grade 3 or 4 toxicity.74,75 Studies that 
evaluated the safety and tolerability of a 60-minute rituximab 
infusion (total dose given over 60 minutes, with standard 
premedications and corticosteroids) also proved to be safe 
and tolerable, with no Grade 3 or 4 toxicities.76,77 In addi-
tion to the published studies, a large multicenter Phase III 
trial evaluating the safety of a 90-minute rituximab infusion 
in patients with previously untreated diffuse large B cell or 
follicular non-Hodgkin’s lymphoma is ongoing. The results 
of these studies suggest that rapid infusion of rituximab at 
375 mg/m2 is safe and tolerable. While many institutions may 
have adopted the rapid infusion of rituximab into their current 
practice, several questions regarding the indications and tim-
ing for rapid infusions, eligible patient populations, and  the 
impact on response rates have not been fully answered.
Conclusion
The introduction of rituximab greatly expands the treatment 
options for patients diagnosed with CLL. Single-agent 
rituximab showed modest activity in previously treated and 
untreated CLL, but is a therapeutic option for patients unfit 
for fludarabine-based regimens because of advanced age and/
or poor performance status. Several large randomized trials 
comparing fludarabine with FC demonstrated significantly 
improved response rates, progression-free survival, and treat-
ment-free survival with FC,29–31 but a demonstrable improve-
ment in overall survival remained elusive until   Keating et al 
combined rituximab with FC (ie, FCR). Using the FCR 
regimen, the GCLLSG demonstrated an overall survival 
advantage over FC and established a new standard of care for 
patients under the age of 65 years. However, similar success 
in biologic unfit patients remains to be a challenge.33
Additionally, we have also seen important progress in 
understanding the biology of CLL. This progress has been 
seen in the development of clinical staging systems and 
identification of complex genetic aberrations indicative 
of high-risk disease using immunologic, cytogenetic, and 
molecular techniques. While the watch and wait paradigm is 
still the standard, the benefit of early intervention in high-risk 
patients needs further exploration, especially in patients with 
17p deletions. Patients harboring a 17p deletion are particu-
larly hard to treat, given the poor responses and poor survival 
observed with single-agent rituximab and FCR. Overall, 
rituximab has contributed markedly to improved outcomes in 
CLL and has changed the way CLL is viewed and treated.
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